Summary:
In 1,864 adults with T2D (HbA1c 7.0-10.5%) on stable metformin ± sulfonylurea, once-daily oral semaglutide (3, 7, or 14 mg) for 78 weeks at 7 mg reduced HbA1c 1.0% and 14 mg reduced 1.3% vs 0.8% with sitagliptin; weight loss 1.6-2.5 kg vs 0.6 kg; 57.4% achieved <7.0% vs 34.2% compared to sitagliptin 100 mg daily, with more GI side effects at higher doses; 3 mg showed no significant benefit over sitagliptin.
| PICO | Description |
|---|---|
| Population | 1,864 adults with T2D (HbA1c 7.0-10.5%) on metformin ± sulfonylurea. |
| Intervention | Oral semaglutide 3, 7, or 14 mg daily for 78 weeks with dose escalation. |
| Comparison | Sitagliptin 100 mg daily (maximum approved dose). |
| Outcome | HbA1c -1.0% (7mg), -1.3% (14mg) vs -0.8%. Target <7%: 57.4% vs 34.2%. |
Oral Semaglutide vs Sitagliptin (PIONEER 3)
RCT · type 2 diabetes · 78 weeks
Oral semaglutide 7 and 14 mg cut HbA1c and body weight more than sitagliptin, with nearly double the patients reaching <7.0%. GI effects rose with dose; 3 mg was no better than sitagliptin.
Clinical Context
Oral semaglutide uses SNAC absorption enhancer requiring empty stomach, limited water, 30-minute fast before eating.
Clinical Pearls
1. 3 mg Dose Is Not Therapeutic: Starting dose only; titrate to at least 7 mg, preferably 14 mg.
2. 14 mg Dose Approaches Injectable Efficacy: 1.3% HbA1c reduction approaches injectable semaglutide.
3. Target Achievement Nearly Doubles: 57% vs 34% achieved <7.0%.
4. Administration Requirements Critical: Empty stomach, ≤120 mL water, 30-min fast before eating/other meds.
Practical Application
For patients preferring oral, can adhere to administration requirements. Assess morning routine before prescribing.
Study Limitations
26-week primary endpoint. Real-world adherence to administration requirements may be lower.
Bottom Line
Oral semaglutide 7-14 mg provides superior glycemic control vs sitagliptin for injection-averse patients who can follow administration requirements.
Source: Rosenstock J, et al. “Oral Semaglutide vs Sitagliptin in T2D (PIONEER 3).” JAMA, 2019. Read article